JG
NERV icon

Jefferies Group’s Minerva Neurosciences NERV Stock Holding History

Jefferies Group’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,163
Closed -$171K – 2530
2018
Q4 		$171K Hold
3,163
– – ﹤0.01% 1876
2018
Q3 		$318K Buy
+3,163
New +$238K ﹤0.01% 1847

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Jefferies Group's NERV Position: Q4 2019 in Review

Jefferies Group sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 1,559 shares — an estimated $97K sold.

Jefferies Group first reported a position in NERV in Q2 2017 and held it in 6 quarters. The position peaked at $2.64M in Q2 2018. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

  • Jefferies Group reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
  • Jefferies Group sold 1,559 Minerva Neurosciences shares in Q4 2019, an estimated $97K.
  • Jefferies Group first reported a position in Minerva Neurosciences in Q2 2017 and held it in 6 quarters.
  • Jefferies Group's Minerva Neurosciences position peaked at $2.64M in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.